Article
Medicine, Research & Experimental
Yuqiang Chen, Lisha Zhang, Qin Xue, Niansong Wang
Summary: This study explored the infection profile and risk factors for mortality in patients with end-stage renal disease (ESRD) attributable to systemic lupus erythematosus (SLE). The results showed that infections were common in these patients, and several risk factors were associated with higher mortality. The study recommended prompt initiation of antibiotics once infection is identified.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
(2022)
Article
Rheumatology
Renata Baronaite Hansen, Titilola Falasinnu, Mikkel Faurschou, Soren Jacobsen, Julia F. Simard
Summary: This study aimed to determine whether diabetes mellitus (DM) increases the risk of end-stage renal disease (ESRD) in patients with systemic lupus erythematosus (SLE). The findings show that SLE patients with DM have a 3 times higher risk of developing ESRD compared to SLE patients without DM.
ARTHRITIS CARE & RESEARCH
(2023)
Review
Medicine, General & Internal
Johan Frostegard
Summary: The prognosis in systemic lupus erythematosus (SLE) has improved, but cardiovascular disease (CVD) still remains a significant clinical problem. Atherosclerosis and antiphospholipid antibody syndrome are the main underlying causes of CVD in SLE. Inflammation and low levels of anti-phosphorylcholine also contribute to the increased risk of CVD in SLE. Close monitoring and treatment of both traditional and non-traditional risk factors are important.
JOURNAL OF INTERNAL MEDICINE
(2023)
Article
Medicine, Research & Experimental
Yi Zhang, Lingzhen Hu, Xiang Li, Liheng Chen, Xuyan Yang
Summary: Patients with active SLE had higher levels of serum Slit2, especially those with chronic kidney disease (CKD), indicating a potential correlation between serum Slit2 levels and disease activity in SLE. Moreover, renal expression of Slit2 and its receptor Robo1 were elevated in patients with lupus nephritis.
CLINICAL AND EXPERIMENTAL MEDICINE
(2021)
Article
Rheumatology
Chunhuan Lao, Philippa Van Dantzig, Douglas White, Kannaiyan Rabindranath, Donna Foxall, Ross Lawrenson
Summary: This study examines the prevalence and outcomes of end-stage kidney disease (ESKD) among systemic lupus erythematosus (SLE) patients. The study finds that SLE patients have a high prevalence rate of ESKD, with higher risks for men and Maori and Pacific patients. Maori patients with ESKD have poorer survival compared to other patients.
RHEUMATOLOGY INTERNATIONAL
(2023)
Review
Nutrition & Dietetics
Karen Pesqueda-Cendejas, Melissa Rivera-Escoto, Monica R. Meza-Meza, Bertha Campos-Lopez, Isela Parra-Rojas, Margarita Montoya-Buelna, Ulises de la Cruz-mosso
Summary: Systemic lupus erythematosus (SLE) is characterized by a bimodal mortality pattern related to clinical disease activity and cardiovascular disease (CVD). The high prevalence of CVD in SLE patients is believed to be caused by the complex interaction between traditional and non-traditional CVD risk factors. Additionally, nutritional approaches have the potential to reduce SLE severity and organ damage by modulating the development of CVD risk factors.
Review
Immunology
Xiaohong Lu, YanHua Wang, Jing Zhang, Dan Pu, Nan Hu, Jing Luo, Qi An, Lan He
Summary: The systematic review and meta-analysis found that patients with systemic lupus erythematosus (SLE) have a higher risk of developing cardiovascular disease (CVD) compared to the general or healthy population, and the risk of CVD in lupus nephritis (LN) patients is significantly higher than in SLE patients.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Rheumatology
Nikolaos Koletsos, Eugenia Gkaliagkousi, Antonios Lazaridis, Areti Triantafyllou, Panagiota Anyfanti, Panagiotis Dolgyras, Konstantina Dipla, Vasiliki Galanopoulou, Spyros Aslanidis, Stella Douma
Summary: This study demonstrates that patients with SLE show reduced microvascular reactivity during reperfusion, even in the absence of overt cardiovascular disease or risk factors, compared to controls. These findings indicate that skin microvascular dysfunction is present in SLE independent of the cardiovascular burden these patients carry, suggesting it may serve as an early indicator of vascular damage.
Article
Immunology
Huajian Chen, Li Huang, Xinyue Jiang, Yue Wang, Yan Bian, Shumei Ma, Xiaodong Liu
Summary: The study identified six key genes and developed an effective SLE disease risk prediction model through analysis of gene expression datasets and model construction.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Lu Xiao, Wei Xiao, Shudian Lin
Summary: This study aimed to identify the key genes related to active renal involvement in patients with systemic lupus erythematosus (SLE). A total of 182 differentially expressed genes (DEGs) were identified, and 12 hub genes were found to be positively associated with SLE Disease Activity Index (SLEDAI). The combination model of these hub genes showed certain diagnostic accuracy in detecting renal involvement with high disease activity in SLE patients.
FRONTIERS IN MEDICINE
(2022)
Article
Immunology
Haiping Xing, Haiyu Pang, Tian Du, Xufei Yang, Jing Zhang, Mengtao Li, Shuyang Zhang
Summary: In this study, atherosclerotic risk prediction model was built for SLE patients using RNA sequencing and differential expression analysis. The model, incorporating one gene and two clinical factors, demonstrated relatively high discrimination and calibration performance, providing valuable assistance for identifying atherosclerosis in SLE patients, especially asymptomatic ones.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Paul Curtiss, Amanda M. Walker, Benjamin F. Chong
Summary: This study reviewed patient cohorts and populations to investigate the progression of cutaneous lupus to systemic lupus. The study found variations in the progression rates between adult and pediatric groups, which were attributed to differences in patient populations, study design, diagnostic criteria, and follow-up time. Risk factors associated with the development of systemic lupus included positive anti-nuclear antibodies, hematologic abnormalities, and a higher number of lupus classification criteria at baseline.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Ni Sang, Rui-Chen Gao, Meng-Yao Zhang, Zhen-Zhen Wu, Zhen-Gang Wu, Guo-Cui Wu
Summary: This study aimed to evaluate the causal relationship between sleep traits and systemic lupus erythematosus (SLE) using genetic instruments. The results showed no evidence of a bidirectional causal relationship between sleep traits and SLE.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Rheumatology
Gabriel Figueroa-Parra, Jose A. Meade-Aguilar, Cassondra A. Hulshizer, Tina M. Gunderson, Alanna M. Chamberlain, Uma Thanarajasingam, Kurt J. Greenlund, Kamil E. Barbour, Cynthia S. Crowson, Ali Duarte-Garcia
Summary: The study aimed to assess the prevalence and incidence of multimorbidity and its association with the SLICC/ACR damage index (SDI) among patients with SLE. The results showed that patients with SLE were more likely to have multimorbidity, both before and after the onset of the disease. Multimorbidity was driven by both SDI-related and unrelated conditions.
Review
Pediatrics
Thomas Dowsett, Louise Oni
Summary: This review article summarizes the current literature surrounding the management of pediatric lupus nephritis. The current treatment approach involves induction therapy to induce remission followed by maintenance immunosuppressive therapy. However, the complete response rates in lupus nephritis are still inadequate and disease flares are common. Progression to chronic kidney disease is also a concern. Current clinical trials are focused on the use of biologic agents as adjuncts to current therapy. Improved outcomes in pediatric lupus nephritis are urgently needed and the use of biomarkers and scientific studies offer hope for better understanding and management.
CURRENT OPINION IN PEDIATRICS
(2022)